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Abstract 
As a sequel to last week’s article on the fundamentals of clinical trial design, this article 
tackles related controversial issues: noninferiority trials; the value of factorial designs; the 
importance and challenges of strategy trials; Data Monitoring Committees (including when to 
stop a trial early); and the role of adaptive designs. All topics are illustrated by relevant 
examples from cardiology trials. 
 
<KW>Key words: Noninferiority trials; Factorial designs; Strategy trials, Data Monitoring 
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Abbreviations 
ACS = acute coronary syndrome 
CABG = coronary artery bypass graft 
CI = confidence interval 
CV = cardiovascular 
DMC = Data Monitoring Committee 
FDA = Food and Drug Administration 
MACE = major adverse cardiovascular event 
OMT = optimal medical therapy 
PCI = percutaneous coronary intervention 
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Introduction  
Randomized controlled trials are the cornerstone of clinical guidelines informing best 
therapeutic practices, however their design and interpretation may be complex and nuanced. 
This review explores challenging issues that may arise and builds on the fundamentals of trial 
design covered in last week’s paper. Specifically, we offer guidance on how to design and 
interpret noninferiority trials where the goal is to demonstrate that the efficacy of a new 
treatment is as good as that achieved with a standard treatment. Factorial trials, where 2 (or 
more) therapeutic issues are simultaneously evaluated in the same study, present an 
interesting opportunity that should be considered more often in cardiology research. Trials 
that compare substantially different alternative treatment strategies can be of great value in 
enhancing good patient management, and we present guidance on the topic to stimulate 
greater interest in overcoming the difficulties in undertaking such pragmatic studies. All 
major cardiology trials have both ethical and practical needs for data monitoring of the 
accumulating evidence over time. We provide insights into how Data Monitoring Committees 
(DMCs) should function, offering statistical guidelines and practical decision-making 
considerations as to when to stop a trial early. Finally, there is a growing interest in adaptive 
designs, but few instances of their implementation in cardiology trials. We focus on adaptive 
sample size re-estimation and enrichment strategies, with guidance on when and how they 
may be used. All of these issues are illustrated by experiences from actual cardiology trials, 
demonstrating the real-world implications of trial design decisions. 
Noninferiority Trials 
Increasingly, major trials are conducted to see if the efficacy of a new treatment is as good as 
a standard treatment (1-3). The new treatment usually has some other advantage (e.g., fewer 
side effects, ease of administration, lower cost), making it worthwhile to demonstrate 
noninferiority in respect of efficacy.  
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The standard approach to designing a noninferiority trial is to predefine a 
noninferiority margin, commonly called delta, for the primary endpoint. This is the smallest 
treatment difference, which, if true, would mean that the new treatment is declared inferior. 
This is based on the belief that any difference smaller than this would constitute clinically 
accepted grounds of “therapeutic interchangeability” (4). The trial’s conclusions then depend 
on where the 95% confidence interval (CI) for the treatment difference ends up in relation to 
this margin. If the upper bound of the 2-sided 95% CI is less than delta, one can claim 
evidence that the new treatment is noninferior. 
For instance, the ACUITY trial compared bivalirudin with the standard treatment of 
heparin plus a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndrome (ACS) 
for 30-day composite ischemia (death, myocardial infarction [MI] or revascularization)(5). 
The noninferiority margin was set at a relative risk of 1.25. The trial’s findings revealed 
composite ischemia rates of 7.8% and 7.3% in the bivalirudin and control groups, 
respectively (relative risk 1.08; 95% CI: 0.93 to 1.24). Because the upper bound of the CI of 
1.24 was less than the pre-declared delta of 1.25, one can conclude that there is evidence of 
noninferiority. The reason this matters is that bivalirudin also had a markedly lower risk of 
major bleeding, an important consideration when choosing between antithrombin therapies. 
A common misunderstanding is that lack of a statistically significant difference 
between 2 therapies implies that they are equivalent. For instance, the INSIGHT trial 
compared nifedipine with co-amilozide in hypertension. The authors concluded that the 
treatments were “equally effective in preventing cardiovascular complications”, on the basis 
of p = 0.35 for the primary composite endpoint of cardiovascular (CV) death, MI, heart 
failure, or stroke (6). But the observed relative risk of 1.10 had a 95% CI of 0.91 to 1.34. This 
includes up to a 34% excess risk on nifedipine, making it unwise to conclude that nifedipine 
is as good as (i.e., noninferior to) co-amilozide. 
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Figure 1 shows a conceptual plot of how to interpret the results of noninferiority 
trials. Scenario C (noninferior) indicates what happened in the ACUITY trial. If we suppose 
that the INSIGHT trial had the same delta, 1.25, then it would have fallen under scenario F 
(inconclusive). Had more patients been enrolled, the 95% CI would have narrowed, and 
noninferiority might then have been declared. 
 Sometimes, the treatment effect (and its delta) is expressed as a difference in 
percentages, rather than as a relative risk or hazard ratio (the argument being that absolute 
differences are more clinically relevant than relative risks). For instance, the OPTIMIZE trial 
compared a 3-month versus a 12-month duration of dual antiplatelet therapy after 
implantation of a zotarolimus-eluting stent (7). For the composite primary endpoint of net 
adverse clinical events (death, MI, stroke, or major bleed) at 1 year, a 2.7% percentage 
difference was set as the noninferiority margin. The observed difference was +0.2%, with a 
95% CI of -1.5% to +1.9%. Because this excludes the margin of +2.7%, noninferiority of the 
3-month duration of treatment was claimed. 
This example raises a few issues. When the noninferiority margin is a difference in 
percentages, it becomes easier (perhaps too easy) to achieve noninferiority if the overall event 
rate is lower than expected. OPTIMIZE had an anticipated 9% event rate in the control arm, 
but the observed event rate was 6%. This made the 2.7% margin equivalent to a relative risk 
margin of 1.45, which is undesirably large. Conversely, if the overall event rate is greater 
than expected, it may become unreasonably difficult to achieve noninferiority. The opposite 
considerations of anticipated versus observed event rates apply if a relative risk is chosen for 
the margin. 
Also, the endpoint chosen in OPTIMIZE was not of optimal relevance. The true issue 
in considering a shorter period of dual antiplatelet treatment concerns the balance between 
the increased risks of stent thrombosis and MI against the reduced risk of major bleeding. To 
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force these diverse endpoints into a single composite would bias results toward the null. A 
preferable approach is to pre-specify and study separately-powered efficacy and safety 
endpoints, typically one for superiority and one for noninferiority. However, a very large 
sample size may be required to adequately power both the efficacy and safety endpoints. 
A composite net adverse clinical events endpoint, consisting of combined safety and 
efficacy endpoints, has been used in some trials, reflecting the recognition that both types of 
endpoints (e.g., major bleeding and stent thrombosis) are deleterious and strongly associated 
with subsequent mortality. However, interpretation of such a combined safety and efficacy 
endpoint may be challenging, especially if the different components do not have similar 
impacts on patient well-being or survival. Moreover, because safety and efficacy endpoints 
often move in different directions (e.g., in response to more potent antithrombotic therapies), 
their combination in a composite endpoint may mask differences between therapies, making 
careful examination of each component measure essential. 
A key question is the choice of noninferiority margin, which has implications for the 
required trial size. Power calculations for noninferiority trials (not presented here) indicate 
that trial size is inversely proportional to the square of the margin delta. For instance, had 
ACUITY chosen a 10% increase, rather than a 25% increase (i.e., relative risk 1.1, rather than 
1.25), more than 6 times as many patients would have been required for the same power (i.e., 
over 50,000 in total). Thus, the choice of margin requires a realistic balancing of scientific 
goals with an achievable sample size. 
The choice of margin is sometimes related to prior knowledge of the efficacy of the 
active control compared to placebo. A sensible goal is that the new treatment should preserve 
at least 50% of the effect demonstrated in prior trials of the control treatment against placebo 
(the so-called “putative placebo” approach). For instance, in the CONVINCE trial of 
verapamil versus standard antihypertensive treatment with a diuretic  or beta-blocker, the 
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noninferiority margin for the composite of stroke, MI, or CV death was set at a hazard ratio 
of 1.16 (8). This was because of the need for evidence that verapamil was at least half as 
effective as the standard treatment, relative to placebo. Regulatory agencies accept this 
method to establish a noninferiority margin, and provide guidance for its determination (1). 
In addition to the assumed event rates, margin, and desired power, the sample size of 
a noninferiority trial depends on whether the delta will be tested against the upper bound of a 
1- or 2-sided 95% CI (the latter being equivalent to a 1-sided 97.5% confidence limit). The 
latter conservative approach is the standard for regulatory approval of new pharmaceuticals 
(and many devices). However, some devices, such as the FilterWire EX system to prevent 
distal embolization during percutaneous coronary intervention (PCI) of diseased saphenous 
vein grafts in the FIRE trial (9), have been approved on the basis of a noninferiority design 
with a 1-sided alpha of 5%. Utilizing a 1-sided alpha of 5%, rather than 2.5%, reduces the 
sample size by approximately 20%, although this is generally frowned upon. Accepting 
greater alpha error may be acceptable, however, when the experimental device provides 
additional benefits not evident in the primary endpoint.  
A noninferiority design may also be applied to exclude a safety concern in a treatment 
with known efficacy. Such safety trials can include comparison of the experimental agent to 
an active comparator. (e.g., as in the ENTRACTE trial performed to exclude excess CV risk 
for tocilizumab compared to etanercept in patients with rheumatoid arthritis) (10). But in type 
2 diabetes, Food and Drug Administration (FDA) guidance requires assessment of the CV 
risk of any new drug relative to placebo (11). Many such placebo-controlled trials in high-
risk patients already on appropriate antiglycemic therapy are either currently in progress or 
recently completed. The primary safety endpoint is typically the composite of CV death, MI, 
and stroke, and the noninferiority margin is set at a hazard ratio of 1.3. This requires a trial of 
many thousands of patients because approximately 700 primary events are needed to provide 
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convincing evidence of noninferiority. For a new, effective antidiabetic drug, the FDA also 
requires preliminary evidence of CV safety for initial approval, using a hazard ratio 
noninferiority margin of 1.8. The larger safety trial to confirm noninferiority on the basis of 
the tougher  margin of 1.3 then ensues. 
It is sometimes argued that noninferiority trials should emphasize a per-protocol (or 
as-treated) analysis, rather than analysis by intention-to-treat, thereby excluding any follow-
up after a patient withdraws from randomized treatment (or after a short period following 
withdrawal to capture rebound events). The logic is that including off-treatment follow-up 
(possibly with crossovers) may dilute any real treatment differences, thereby artificially 
enhancing any claim of noninferiority. However, per-protocol and as-treated analyses 
introduce other biases. We suggest that both types of analyses be presented in noninferiority 
trials, hopefully demonstrating a consistency of findings. 
When undertaking a noninferiority trial, one can also propose a superiority 
hypothesis, with no statistical penalty. That is, once the trial results confirm noninferiority, 
one can go on to test for superiority (see scenario A in Figure 1). For instance, some CV 
safety trials of antidiabetic drugs have been made larger to accommodate this superiority 
hypothesis. One such trial (EMPA-REG OUTCOME) of empagliflozin versus placebo 
recently demonstrated some evidence of a reduction in the primary endpoint of CV death, MI, 
or stroke, with a hazard ratio of 0.86 (95% CI: 0.74 to 0.99; p = 0.04), while also showing a 
significant reduction in all-cause death with a hazard ratio of 0.68 (95% CI: 0.57 to 0.82, p 
<0.001)(12). 
Factorial Designs 
Sometimes, one can pursue 2 separate treatment comparisons within the same major 
trial by randomizing each patient twice: once to treatment A versus its control and, at the 
same time, to treatment B and its control. This is known as a 2-way factorial design (13,14). 
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Factorial designs have numerous practical benefits, such as adding in a second randomization 
within the framework of a trial funded for a different purpose, affording the opportunity to 
investigate an inexpensive treatment that would otherwise be difficult to fund and test in its 
own trial. For instance, the HOPE factorial trial studied ramipril versus placebo and then also 
vitamin E versus its placebo in high-risk patients (15,16). Ramipril significantly reduced CV 
events, whereas vitamin E did not. 
In planning a factorial design, one presumes that the treatment effect in 1 randomized 
comparison is not likely to depend on the other randomized treatment: that is, there is no 
expectation of an interaction between the 2 randomized treatments. Thus, the trial is powered 
to examine the main effects of the 2 randomized comparisons separately. By doing so, one 
neatly gets “2 trials for the price of 1”; that is, in principle adding in the second 
randomization does not increase the trial size. In practice, it may be wise to somewhat inflate 
trial size when a factorial design is contemplated because: 1) if both treatments are effective, 
the overall event rate will be lower; and 2) one may wish to guard against a modest 
quantitative interaction being present. 
The CURRENT OASIS 7 trial randomized 25,086 ACS patients referred for an 
invasive strategy to both: 1) double-dose versus standard-dose clopidogrel; and 2) higher-
dose versus lower-dose aspirin (17). The primary outcome was CV death, MI, or stroke 
within 30 days, and the findings are shown in Table 1. The 2 main effect analyses showed 
that neither the clopidogrel dose nor the aspirin dose appeared to have any effect on the 
primary endpoint, p = 0.30 and p = 0.61 respectively. Exploring the potential interaction 
between the 2 drug doses, however, revealed a curious finding: the observed event rate was 
lower on double-dose than standard-dose clopidogrel (3.8% vs. 4.6%) when given with 
higher-dose aspirin, but this was reversed (4.5% vs. 4.2%) when given with lower-dose 
aspirin. This apparent qualitative interaction did reach conventional statistical significance, 
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interaction p = 0.04. The authors believed that this unexpected finding lacks a known 
biological mechanism and may be due to the play of chance, which is a reasonable 
supposition. Conversely, if a possible biological explanation for the interaction may be 
posited, the validity of the conclusions drawn from both arms may be jeopardized, an 
inherent risk of factorial designs. Factorial designs should therefore only be contemplated 
when the expectation of a real interaction between the 2 therapies is low. In principle, one can 
still undertake a factorial trial when a plausible interaction between the 2 treatment factors is 
contemplated, but this would require a major increase in trial size to be adequately powered 
to detect such an interaction. 
Another useful option is a partial (or nested) factorial design, where all recruited 
patients get 1 random treatment allocation, but only some patients are eligible for the second 
randomized treatment. For instance, the HORIZONS-AMI trial randomized 3,602 ST-
segment elevation MI patients to bivalirudin versus heparin plus a glycoprotein IIb/IIIa 
inhibitor (in a 1:1 ratio)(18,19). Among these patients, 3,006 met additional anatomic 
inclusion criteria and underwent a second randomization to PCI with paclitaxel-eluting versus 
bare-metal stents (in a 3:1 ratio).  
Occasionally the factorial design can take on more than 2 treatment factors. For 
instance, the ISIS 4 trial randomized 58,050 patients with MI to: 1) oral captopril versus 
placebo; 2) oral mononitrate versus placebo; and 3) intravenous magnesium sulfate versus 
open control in a 2 × 2 × 2 factorial design (20). Finally, the MATRIX trial is an example of 
a 3-level randomization with a nested factorial approach. In MATRIX, 8,404 patients with 
ACS undergoing cardiac catheterization were randomized to radial versus femoral vascular 
access. Among this group, 7,213 patients in whom PCI was selected for treatment were 
randomized again to procedural anticoagulation with heparin versus bivalirudin. Finally, the 
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3,610 bivalirudin-assigned patients were randomized a third time to either a post-procedural 
prolonged bivalirudin infusion or to no infusion (21,22). 
When circumstances are right, the factorial design is a useful means of investigating 2 
(or more) different treatment innovations within 1 trial. Overall, trialists need to give more 
attention to the imaginative use of factorial designs. 
Trials of Alternative Treatment Strategies 
Trials of fundamentally different treatment strategies, for example, surgery versus PCI 
or medical therapy, or invasive versus conservative approaches in patients with ACS, are an 
exciting challenge and can make a substantial impact on guidelines and clinical practice 
(23,24). Such “strategy” trials are, however, more difficult to undertake than studies 
comparing different drugs or different devices to each other. 
When the randomized strategies differ substantially in their perception by both 
investigators and patients, particular challenges arise. Investigators (often across specialties 
[e.g., cardiac surgeons and interventional cardiologists]) need to accept that the patient may 
truly receive either strategy without being disadvantaged (i.e., a state of equipoise is indeed 
present). Even if solid evidence is lacking, physicians (and patients) may express strongly 
held beliefs in the superiority of one treatment compared to another, based either on 
anecdotal experiences or reports, nondefinitive evidence (e.g., uncontrolled observational 
comparisons or small randomized trials), or prior positive trials using surrogate endpoints. 
These preconceived beliefs can make enrollment more difficult, and may result in a biased 
cohort being recruited. Obtaining informed patient consent is also less routine in strategy 
trials than in standard randomized drug or device studies. Strategy trials also typically require 
multidisciplinary cooperation, greater resources, and a longer period for full recruitment, and 
are thus more expensive. Strategy trials often lack a single funding source from industry, and 
therefore often require pure governmental and/or institutional support, collaboration between 
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multiple companies, or a private-public partnership. Thus, major challenges in strategy trials 
include randomizing a high enough proportion of eligible patients in a reasonable timeframe, 
and raising appropriate funds. 
For instance, the ISCHEMIA trial is a major multinational trial of routine invasive 
versus conservative strategies in patients with stable coronary disease and at least moderate 
ischemia (25). A strong evidence-based case can be made for either approach in such patients 
(26). A prior survey of interested cardiologists asked if they would enroll their eligible 
patients in a randomized trial with a 50% chance of being conservatively managed without 
cardiac catheterization; 80% responded positively (27). ISCHEMIA initially planned to 
recruit 8,000 patients, but after more than 2 years, only ~2,000 patients have been 
randomized, which may require a protocol amendment to reduce the sample size. Such lower 
than desired recruitment is a common problem with strategy trials. 
Strategy trials are particularly important when evaluating a new therapeutic approach. 
For instance, transcatheter aortic valve replacement has emerged as an alternative to surgical 
aortic valve replacement in patients at high and prohibitive operative risk (28,29). Ongoing 
trials are now being performed in patients at lower surgical risk. Key aspects here are to 
decide when in the learning curve of such a new technology one should undertake such a 
trial; to define the risk profile of patients that should initially be recruited; and to create the 
right collaborative atmosphere for general cardiologists, interventionalists, and surgeons to 
participate. 
The results of strategy trials require careful interpretation, especially when crossovers 
occur. For instance, the COURAGE trial studied optimal medical therapy (OMT) with and 
without initial PCI in 2,287 patients with stable coronary disease (30). The primary endpoint, 
the composite rate of death or nonfatal MI, showed no significant difference between the PCI 
and medical therapy groups after a median 4.6 years of follow-up. A naive interpretation is 
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that PCI is no better than medical therapy (and thus PCI should never be performed), but this 
ignores the strategic concept of the trial. In COURAGE, 32.5% of patients assigned to OMT 
went on to receive revascularization (mostly PCI) during follow-up, primarily for progressive 
or unstable symptoms. Thus, the trial really compared “PCI (plus OMT) now” with “OMT 
now, with the option of later PCI (or coronary artery bypass graft (CABG)), as needed.” The 
pure question “does PCI improve prognosis?” is not directly answerable because the 
investigators could not continue with medical therapy alone. 
An additional concern of particular relevance to strategy trials is that given their 
inherently protracted nature (slow recruitment with long follow-up), the standard of care 
frequently evolves prior to their finish. For instance, in the SYNTAX trial, CABG was shown 
to be superior to PCI using a first-generation paclitaxel-eluting stent (31). However, by the 
time SYNTAX was completed, second-generation drug-eluting stents had been developed, 
which have been associated with reduced rates of death, MI, and repeat revascularization 
compared with paclitaxel-eluting stents (32). Studies have suggested that this advance alone 
might have eliminated the difference between the 2 strategies (33). Confirming such a 
hypothesis requires performance of another time-consuming and costly randomized trial, 
which, in turn, risks further advances in technology before its completion. 
Despite the practical difficulties in undertaking randomized trials of alternative 
strategies, they are of key importance in evaluating radically different approaches to patient 
care. Otherwise, we are forced to rely on nonrandomized comparisons on the basis of patient 
registries. They, too, provide a wealth of interesting data, but always with the caveat that 
substantial selection bias is typically present, resulting in unmeasured confounders that 
cannot be accounted for in statistical analysis (34,35). 
One exciting development is the growth of pragmatic trials that are embedded within 
routine care delivery (i.e., trials with patient registries, such as the TASTE trial of thrombus 
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aspiration for MI (36)). Such trials greatly enhance patient representativeness, recruitment, 
and follow-up, with associated reduced trial costs. However, they are best suited to assess 
endpoints reliably tracked in administrative databases, such as all-cause mortality. 
Data Monitoring for Efficacy, Safety and Futility 
Most major randomized trials require interim analyses of the accumulating outcome 
data by treatment group. Such unblinded interim analyses are produced by an independent 
statistician and are evaluated by an independent DMC, comprising several clinicians plus a 
statistician, all of whom have no other involvement in the trial and operate under strict 
confidentiality (37,38). 
The main DMC responsibility is to protect patient safety, that is, to identify and react 
to any evidence of harm occurring to patients, especially on the new treatment. Adverse 
events may relate to predefined safety issues (e.g., bleeding on antiplatelet drugs), unexpected 
event types, or inferiority with regard to primary or secondary event outcomes. The DMC 
should meet regularly so that any ethical concerns as regards potential harm can be dealt with 
in a timely fashion. If safety issues become evident, the DMC may request more data 
analyses, and schedule follow-up meetings more frequently. The DMC can recommend to the 
study leadership that the trial be stopped or altered. However, given the likelihood of chance 
variations in repeated looks at accumulating data, major alterations should only be 
recommended if truly convincing evidence of harm is present, with a lower threshold to 
modify or stop the trial for concerns relating to increased mortality, as opposed to other 
endpoints. 
A second DMC responsibility may be to evaluate whether there is overwhelming 
evidence for superiority of the new treatment, which is sufficiently convincing to merit 
stopping the trial early. However, trials that are stopped early tend to overestimate true 
treatment effects. Thus, early trial stoppage should only be recommended for situations in 
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which continuing would truly place the control group patients at harm (e.g., increased 
mortality, resulting in an ethical imperative to unblind and expedite approval of the 
experimental treatment).  
Sometimes there is a third futility issue for the DMC to consider. That is, does the 
accumulating evidence indicate that the new treatment lacks efficacy? If there is little chance 
of the trial achieving a clinically-relevant positive outcome, the trial may be stopped early for 
futility. Such a decision needs careful consideration, as even if the primary endpoint lacks 
efficacy, secondary endpoints with real clinical value may emerge as positive (even if only 
hypothesis-generating). 
A further DMC responsibility is to look at trial quality issues. For instance, if 
problems with noncompliance, missing visits/data, or slowness in event adjudication are 
evident, the DMC should provide feedback to the study leadership to facilitate improvements. 
After every interim report and meeting, the DMC needs to promptly communicate its 
recommendations to the trial’s principal investigator (e.g., the chair of the Executive 
Committee) or, sometimes, directly to the trial sponsor in writing (or sooner by phone, if 
major issues of patient safety are apparent). 
All DMC-related activities should be documented in a DMC Charter (39). This should 
include any statistical stopping guidelines (40),
 
recognizing that these are not formal rules: 
the recommendation to stop rests on the wise judgment of the DMC, on the basis of the 
totality of evidence at their disposal, both within the trial and externally. Note that the DMC 
only makes recommendations: any decisions on stopping or modifying the trial are the 
responsibility of the trial Executive Committee or sponsor. So what makes for sensible 
statistical stopping guidelines? 
First, stopping for superiority of a new treatment requires proof beyond a reasonable 
doubt. For example,  p <0.001 is often used, or even p <0.0001 at a relatively early interim 
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analysis. Furthermore, it is wise not to look too early or too often for superiority: 2 or 3 
interim looks should suffice. For instance, the PARADIGM-HF trial of LCZ696 versus 
enalapril in chronic heart failure required p <0.001 for both the composite primary endpoint 
(CV death or hospitalization for heart failure) and CV death alone at its second interim 
analysis, when two-thirds of primary events had occurred (41). Both boundaries were 
crossed, and the DMC duly recommended stopping. 
Of note, achieving a statistical guideline does not automatically mean the trial is 
stopped. For instance, in the SHIFT trial of ivabradine versus placebo, superiority was 
present at the second planned interim analysis for both the composite primary endpoint (CV 
death and hospitalization for heart failure) and all-cause death: p <0.0001 and p = 0.0014, 
respectively (42). The predefined stopping boundary was p <0.001 for the primary endpoint. 
However, the DMC recommended continuation: there were only a few months to go to 
complete enrollment; important subgroup issues needing resolving; event adjudication was 
incomplete; and a previous related trial (BEAUTIFUL) had been neutral (43). Upon trial 
completion, the primary endpoint finding was confirmed, but all-cause mortality was no 
longer significant (p = 0.09). Such “regression to the truth” may often arise. That is, interim 
findings that cross a stopping boundary may be “on a random high,” so that subsequent 
results (if the trial continues) may end up less impressive (44). 
Secondly, stopping for futility has 2 types of statistical guidelines (40,45). One 
approach is to see if the 95% CI for the primary endpoint effect estimate excludes a 
predeclared minimum benefit and then stop the trial early. For instance, in the PERFORM 
trial of terutroban versus aspirin in patients with cerebral ischemic events, the primary 
endpoint was the composite of CV death, MI, or ischemic stroke (46). At the 20
th
 safety 
report, the hazard ratio was 1.04 (95% CI: 0.95 to 1.14). This excluded the predefined 7% 
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benefit (i.e., a hazard ratio of 0.93), and so the DMC recommended that the trial be stopped 
for futility. 
An alternative approach uses conditional power: that is, if the interim data indicate 
only a slim chance of achieving statistical significance upon trial completion, then stopping 
early for futility may be reasonable. This method was applied in the RED-HF trial of 
darbepoetin alfa versus placebo in heart failure patients with anemia (47). Futility was 
considered at each interim analysis: if the conditional power under the protocol-specified 
hazard ratio of 0.8 for the composite primary endpoint (death or heart failure hospitalization) 
was <30%, then the DMC could recommend the trial be stopped. This boundary was 
eventually crossed, but the DMC decided to allow the trial to continue: there were no safety 
concerns and there were significant quality of life improvements (a secondary endpoint). 
Thirdly, stopping for safety usually requires more frequent looks at interim data 
because there is an ethical obligation to stop promptly if a new treatment is causing harm 
(48). Also, the stopping boundary needs to be less stringent; for example, p <0.01 going the 
wrong way for the primary endpoint or all-cause mortality is a useful simple guideline. For 
instance, in the ILLUMINATE trial of torcetrapib versus placebo in high-risk patients, the 
DMC observed 82 deaths in the treatment arm versus 51 deaths with control (p = 0.007), 
which was the prime reason for stopping the trial for harm (49). As a consequence, the 
sponsor withdrew the drug immediately from any further investigation worldwide. 
Similarly, the PALLAS trial of dronedarone versus placebo in permanent atrial 
fibrillation was stopped early when both coprimary endpoints of: 1) stroke, MI, systemic 
embolism, or CV death; and 2) unplanned hospitalization for a CV cause or death, 
demonstrated an excess on dronedarone, both p <0.01 (50). This was particularly surprising, 
given that the earlier ATHENA trial of dronedarone in nonpermanent/paroxysmal atrial 
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fibrillation had shown a highly significant benefit (51). This illustrates the importance of the 
safety role of a DMC, no matter how promising the prior evidence from other sources.  
Stopping early for harm may not relate to the efficacy endpoints, but to specific safety 
problems instead. For instance, at an early interim report, the APPRAISE 2 trial of apixaban 
versus placebo in ACS patients showed significant increases in major bleeding events on 
apixaban (52). Numbers of events were small, but given that the primary efficacy endpoint of 
CV death, MI, or ischemic stroke had thus far showed no benefit, this safety signal was 
deemed sufficient to halt the trial. In such scenarios of potential harm, it is difficult to have a 
statistical stopping guideline that adequately captures the ethical concern, which needs 
balancing against potential benefit regarding efficacy endpoints. Such matters depend on an 
experienced DMC acting wisely, being fully aware of the ethical and practical consequences 
of its actions. 
Let us conclude this section with potential stopping guidelines for a planned placebo-
controlled trial of a new drug for patients at high CV risk. The trial is to recruit 13,000 
patients and completion is planned when 1,600 primary MACE (major adverse CV events) 
have occurred, anticipated to be over 5 years duration in total. This gives 90% power to 
detect a 15% risk reduction (i.e., hazard ratio: 0.85). The trial plans to have 2 interim 
analyses, after 50% and 75% of primary events have occurred, and the proposed stopping 
boundaries for superiority and for futility are shown in Table 2. 
First, the timing of these boundaries recognizes that stopping for either superiority or 
futility should not be contemplated before at least half the trial’s evidence has accumulated. 
The superiority guideline of p <0.0002 reflects the spirit of only stopping when there is 
overwhelming evidence. It is interesting to note that to stop early, the hazard ratio for the 
MACE primary endpoint at the 2 interim looks would need to be <0.768 and <0.806, 
respectively, considerably more beneficial than the 0.85 hazard ratio used in the power 
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calculation. Given the tough stopping boundary, the final p <0.05 for a positive outcome is 
not compromised, and with 1,600 primary events, an observed hazard ratio <0.906 would 
reach statistical significance. 
The stopping guidelines for futility in Table 2 are on the basis of conditional power 
calculations. With 50% of the event data in (800 primary endpoint events), if the hazard ratio 
is only very slightly in a positive direction (hazard ratio >0.979) or in the opposite direction, 
then the trial may stop for futility. Adding a further 25% of events at the second interim 
analysis (1,200 events), one needs a somewhat stronger indication of treatment benefit to 
continue: hazard ratio >0.931 is considered sufficient to stop for futility. Note these are not 
intended as absolute rules. There may be other issues (secondary endpoints, safety concerns, 
subgroup findings, external evidence) that could sway the totality of evidence in a positive or 
negative direction. 
Lastly, note the lack of any formal stopping boundaries for safety. Experience dictates 
that it is impractical to capture all the scenarios and nuances of potential harms in statistical 
guidelines. Rather, the trial DMC will receive frequent safety reports every few months, and 
collectively make judgments on the strength of evidence and the absolute magnitude and 
seriousness of any safety signals. 
Adaptive Designs 
The conventional wisdom in clinical trial design is that once the study protocol is 
finalized, the trial should proceed with no further changes to its intent. Protocol amendments 
are permitted under certain circumstances, but should be made without knowledge of interim 
results by treatment groups: that is, the DMC should have no involvement in such changes. 
Such amendments may be of a practical nature; for example clarifications of patient 
eligibility, endpoint definitions, or drug dose modifications. Amendments in response to 
knowledge of ongoing blinded results for all treatments combined are also permitted. For 
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instance, if the incidence of the primary endpoint pooled across randomized groups is 
substantially lower than anticipated, the target sample size might be increased, the eligibility 
criteria might be changed to recruit higher-risk patients, the duration of follow-up might be 
prolonged, or the primary endpoint might even be altered (e.g., by expanding a composite to 
include additional types of outcomes). In principle, such adaptations are acceptable and carry 
no statistical penalties, although they may prompt concerns that someone involved had an 
awareness of unblinded results. In particular, changing the primary endpoint often evokes 
suspicion, even if unwarranted. 
An emerging and more controversial type of adaptive design is where protocol 
changes are made on the basis of the unblinded interim results (53,54).
 
Both European and 
U.S. regulators have issued guidance on the use (and possible misuse) of such adaptations 
(55,56).
 
It is key that any such potential changes should be predefined in an Adaptive Charter; 
that they should not affect the trial’s overall integrity; and that they should preserve statistical 
rigor: that is, an unbiased verdict is still reached on the treatments’ relative merits. 
The most common adaptation using unblinded data concerns sample size re-
estimation (57). Other types of proposed adaptive designs (54) include seamless phase II/III 
trial designs, whereby from multiple new treatments (e.g., different drug doses), one drops 
some arms at interim analysis on the basis of a surrogate outcome, thereafter examining 
clinical outcomes (58); enrichment designs, in which after the adaptation, selected subgroups 
of patients are preferentially enrolled in whom the event rates were observed to be high or 
evidence of treatment effect appeared particularly robust (59); and “play the winner,” 
whereby the randomization ratio is adjusted to put a higher proportion of future patients on 
the treatment with better interim results (60). All have a methodological appeal, but introduce 
logistical and interpretive challenges. 
21 
 
Hence, we now concentrate on adaptive sample size re-estimation. The logic is that if 
the observed treatment difference for the primary endpoint at a preplanned interim analysis is 
somewhat smaller than that assumed in the original power calculation, trial size may be 
increased to provide adequate power to detect such a more modest treatment effect. For this 
approach to be valid, the interim results need to be in a “promising zone”: that is, 1) the 
observed interim treatment difference, although smaller than hoped for, is still trending in the 
right direction and is big enough to be of clinical relevance, and 2) the expansion in sample 
size takes the conditional power from a current 50%+ to a desired 80%, or higher. Then the 
type I error may be preserved without any statistical adjustments. A sample size increase 
could also be considered if the effect size is preserved, but the endpoint rates at the interim 
analysis are lower than anticipated. 
Figure 2 gives a conceptual outline of how adaptive sample size re-estimation could 
work. Suppose an interim analysis is performed after half the original trial’s results are 
known, and that you are prepared to increase the size (if necessary) up to double that 
originally planned. Then, whether to make any size increase depends on how the observed 
treatment difference compares to the preplanned treatment difference used in the original 
power calculation. If these rates are at least similar, then the trial is “on track” and there is no 
need to increase trial size. We call this the Favorable Zone: in Figure 2, this extends to point 
B, where the observed difference is approximately 90% of pre-planned difference A. 
The Promising Zone refers to the scenario where the observed difference is less than 
hoped for, but conditional power can still be upped to the desirable 90% by increasing the 
sample size. This works fine if the observed difference is at least 66% of the pre-planned 
difference (point C in Figure 2) for which a doubling of size is needed. 
One can then extend the Promising Zone into less optimistic territory, where a 
doubling is still to be done, even though the conditional power cannot make it to the desired 
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90%. For instance, point D in Figure 2 occurs when the interim difference is only slightly 
more than half of the preplanned difference. Doubling the trial size can raise the conditional 
power up to more than 50%; not hopeless, but a gamble as to whether the trial will end up 
positive. If the interim results are worse than that, then one is in the Unfavorable Zone. The 
trial then continues to its original size (unless findings are very unfavorable, in which case 
stopping for futility may be considered). Note that Figure 2 is just conceptual: precise 
statistical details would need to be calculated (57) and specified in an Adaptive Charter. 
Preplanned adaptive sample size re-estimation has been used in 2 trials of cangrelor 
versus clopidogrel in PCI patients. In the CHAMPION-PCI trial, after 70% of patients were 
enrolled, an interim analysis of the 48-h primary endpoint was performed to determine 
whether the intended sample size (9,000 patients) needed expanding up to a maximum of 
15,000 (61,62). The Adaptive Charter also considered potential enrichment with more 
diabetic, troponin-positive, or clopidogrel-naive patients if it would enhance statistical power. 
Unfortunately, there was no interim evidence that cangrelor was superior to clopidogrel, and 
the trial was stopped early for futility. 
The more recent CHAMPION-PHOENIX trial also planned for adaptive sample size 
re-estimation, but, in this instance, because the interim analysis showed clear evidence of 
cangrelor’s superiority, there was no need to expand beyond the original sample size target of 
10,900 patients (63). 
These 2 examples provide a reality check to the burgeoning enthusiasm some trialists 
express about adaptive designs. If a trial is well planned, with a realistic size and alternative 
hypothesis, then the “promising zone” needing actual expansion of trial size is a relatively 
narrow window of opportunity. We favor incorporating preplanned adaptive sample size re-
estimation into clinical trial designs, but investigators should realize that the likelihood of 
actively changing the study size or patient eligibility composition (enrichment) is modest. 
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Thus, organizational simplicity, rather than complex statistical algorithms, is recommended. 
Also, these calculations can be nuanced, and a statistician experienced in adaptive design 
methodology should be involved.  
Despite these caveats, small biotechnology or medical device companies that do not 
have the initial resources to plan an appropriately large trial upfront often consider an 
adaptive approach. Thus, they start with a smaller trial with a potentially unrealistic 
treatment-effect size, and then use “positive” interim data to persuade funders to expand the 
trial. This raises an important concern about adaptive designs: the implicit leaking of interim 
findings beyond the strict confidentiality of the DMC. Only the adaptive decision-makers 
should be privy to interim results. If the rationale for a trial’s adaptive increase in size is 
known, people will infer the nature of the interim findings. It is a matter of debate as to 
whether such wider leakage compromises the trial’s integrity (e.g., by altering patient 
recruitment patterns). 
Conclusions  
 The Central Illustration summarizes the key issues in the diverse collection of 
design topics we have tackled. In this series of 4 consecutive articles on clinical trials (2 on 
analysis and reporting, 2 on design) the aim has been to cover those statistical and scientific 
issues of importance, with a focus on practical insights of relevance to cardiologists. 
There is a substantial literature of a more technical nature that statisticians need to master, but 
such issues tend to be secondary in importance compared with grasping the essential 
nontechnical factors we have discussed, many of which represent the application of common 
sense to trial design and statistics. Some topics we chose not to tackle. For example, Bayesian 
methods are absent, partly because it is hard to do them justice in a few pages, but also 
reflecting our view that they have a limited role: there is a paucity of examples where their 
use in cardiology trials achieved insights not reachable by conventional methods.  
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It is our hope that this series may help clinical trialists and sponsors to more effectively 
design studies, statisticians interfacing with study leadership to bring forward the most 
relevant issues to jointly address, and cardiologists to critically interpret and appraise 
published studies so as to effectively translate clinical trial evidence to patient care. 
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FIGURE LEGENDS 
Central Illustration. Key Challenges in Trial Design 
Figure 1: Possible Outcomes in a Noninferiority Trial (observed difference and 95% CI) 
Caption: Conceptual figure for interpreting non-inferiority trials based on the estimated absolute 
difference, 95% CI and a non-inferiority margin of delta,. The vertical line at 0 represents no treatment 
difference. CIs to the left of the delta line indicate non-inferiority of the new treatment. Note delta can 
sometimes be specified on a relative risk scale. 
 
Figure 2: Conceptual Outline of Sample Size Re-estimation When in the Promising 
Zone 
Caption: Possible outcomes from an interim analysis for adaptive sample size re-estimation. The 
three scenarios are: (1) the Favorable Zone when the observed treatment difference is similar to the 
pre-planned treatment difference, (2) the Promising Zone when the observed difference is less than 
that hoped for but where reasonable conditional power can be achieved by increasing the sample 
size, and (3) the Unfavorable Zone when interim results show poor conditional power and the trial 
continues to its original size. 
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Table 1: Displaying the Results of a Factorial Design: CURRENT OASIS 7 
First main effect Double-dose clopidogrel  Standard-dose clopidogrel 
 (N = 12,520)  (N = 12,566) 
Primary event rates 4.17%  4.43% 
 HR: 0.94; 95% CI: 0.83 to 1.06; p = 0.30 
Second main effect Higher-dose aspirin  Lower-dose aspirin 
 (N = 12,507)  (N = 12,579) 
Primary event rates 4.24%  4.36% 
 HR: 0.97; 95% CI: 0.86 to 1.09; p = 0.61 
Potential interaction Primary events by both treatments simultaneously 
 Double-dose clopidogrel  Standard-dose clopidogrel 
Higher-dose aspirin 3.8%  4.6% 
Lower-dose aspirin 4.5%  4.2% 
Interaction test p = 0.04 
 
CI = confidence interval; HR = hazard ratio. 
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Table 2: Planned Stopping Boundaries for an Event-Driven, 13,000-Patient,Placebo-
Controlled Trial of Patients at High CV Risk 
 
Interim 
Analysis 
Number of 
Primary Events 
Stopping Boundaries* 
  Superiority Futility 
1 800 (50%) 
 
p <0.0002 
HR <0.768 
p >0.758 
HR >0.979 
2 1200 (75%) p <0.0002 
HR <0.806 
p >0.216 
HR >0.931 
Final 1,600 (100%) p <0.05 
HR <0.906 
 
*There are no formal stopping boundaries for safety. 
CV = cardiovascular; HR = hazard ratio. 
 
